---
document_datetime: 2025-09-24 16:10:57
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/omvoh-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: omvoh-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.3144385
conversion_datetime: 2025-12-19 04:57:50.428941
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Omvoh

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|---------------------------------------|----------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type II / EMA/VR/0000264533 | This was an application for a group of variations. | 24/07/2025                          | 22/08/2025                                  | SmPC, Labelling and PL           |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                          | (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.2 Change outside the range of the currently approved pack sizes - Accepted C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted                                                 |            |            |                                  |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|
| Variation type IA_IN / EMA/VR/0000246022 | This was an application for a group of variations. B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted | 04/02/2025 | 22/08/2025 | SmPC, Annex II, Labelling and PL |